Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
The kynurenine pathway (KP) of tryptophan (TRP) catabolism links immune system activation with neurotransmitter signaling. The KP metabolite kynurenic acid (KYNA) is increased in the brains of people with schizophrenia. We tested the extent to which: (1) brain KP enzyme mRNAs, (2) brain KP metabolites, and (3) plasma KP metabolites differed on the basis of elevated cytokines in schizophrenia vs. control groups and the extent to which plasma KP metabolites were associated with cognition and brain volume in patients displaying elevated peripheral cytokines. KP enzyme mRNAs and metabolites were assayed in two independent postmortem brain samples from a total of 71 patients with schizophrenia and 72 controls. Plasma KP metabolites, cognition, and brain volumes were measured in an independent cohort of 96 patients with schizophrenia and 81 healthy controls. Groups were stratified based on elevated vs. normal proinflammatory cytokine mRNA levels. In the prefrontal cortex (PFC), kynurenine (KYN)/TRP ratio, KYNA levels, and mRNA for enzymes, tryptophan dioxygenase (TDO) and kynurenine aminotransferases (KATI/II), were significantly increased in the high cytokine schizophrenia subgroup. KAT mRNAs significantly correlated with mRNA for glial fibrillary acidic protein in patients. In plasma, the high cytokine schizophrenia subgroup displayed an elevated KYN/TRP ratio, which correlated inversely with attention and dorsolateral prefrontal cortex (DLPFC) volume. This study provides further evidence for the role of inflammation in a subgroup of patients with schizophrenia and suggests a molecular mechanism through which inflammation could lead to schizophrenia. Proinflammatory cytokines may elicit conversion of TRP to KYN in the periphery and increase the N-methyl-d-aspartate receptor antagonist KYNA via increased KAT mRNA and possibly more enzyme synthesis activity in brain astrocytes, leading to DLPFC volume loss, and attention impairment in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577
Multiple significance tests: the Bonferroni method
Bland, J. M., & Altman, D. G. (1995) · BMJ · doi:10.1136/bmj.310.6973.170 · Cited by 3,341
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530 · cited 7×
“Importantly, brain KYNs are linked to and influenced by the peripheral KP [9, 27].”
BackgroundMethodInfluentialHilmas, C., Pereira, E. F. R., Alkondon, M., Rassoulpour, A., Schwarcz, R., & Albuquerque, E. X. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07463.2001 · Cited by 859
Perkins, M. N., & Stone, T. W. (1982) · Brain Research · doi:10.1016/0006-8993(82)91048-4 · Cited by 849
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630
Fillman, S. G., Cloonan, N., Catts, V. S., Miller, L. C., Wong, J., McCrossin, T., Cairns, M., & Weickert, C. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.110 · Cited by 609 · cited 7×
“In addition to disturbances in neurotransmitter systems, recent genetic [1], molecular neuropathology [2], and clinical studies [3] have highlighted the importance of immunological factors in the pathogenesis and treatment of”
BackgroundMethodResultInfluentialSelf-citationCannon, T. D., Chung, Y., He, G., Sun, D., Jacobson, A., van Erp, T. G. M., McEwen, S., Addington, J., Bearden, C. E., Cadenhead, K., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.023 · Cited by 599 · cited 1×
“Longitudinal studies will be important if we are to use KP metabolites and immunological factors as clinical biomarkers [53], especially when cytokines are being considered as potential biomarkers aimed at predicting conversion to illness in high-risk samples [54].”
BackgroundIncreased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection
Guillemin, G. J., Kerr, S. J., Smythe, G. A., Smith, D. G., Kapoor, V., Armati, P. J., Croitoru, J., & Brew, B. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00498.x · Cited by 538
Self-citationWhat does plasma CRP tell us about peripheral and central inflammation in depression?
Felger, J. C., Haroon, E., Patel, T. A., Goldsmith, D. R., Wommack, E. C., Woolwine, B. J., Le, N.-A., Feinberg, R., Tansey, M. G., & Miller, A. H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0096-3 · Cited by 448
Wang, A. K., & Miller, B. J. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx035 · Cited by 389
Interleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis
Zunszain, P. A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A. M., Thuret, S., Price, J., & Pariante, C. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.277 · Cited by 388
Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia
Gur, R. E., Cowell, P. E., Latshaw, A., Turetsky, B. I., Grossman, R. I., Arnold, S. E., Bilker, W. B., & Gur, R. C. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.761 · Cited by 368
Fornito, A., Yücel, M., Patti, J., Wood, S. J., & Pantelis, C. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.12.011 · Cited by 359
Increased Levels of Kynurenine and Kynurenic Acid in the CSF of Patients With Schizophrenia
Linderholm, K. R., Skogh, E., Olsson, S. K., Dahl, M.-L., Holtze, M., Engberg, G., Samuelsson, M., & Erhardt, S. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq086 · Cited by 325
Javitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs069 · Cited by 322
Fillman, S. G., Weickert, T. W., Lenroot, R. K., Catts, S. V., Bruggemann, J. M., Catts, V. S., & Weickert, C. S. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.90 · Cited by 270 · cited 5×
“cohorts [2, 4, 5, 42] and others have reported similar findings [55].”
BackgroundMethodResultInfluentialSelf-citationThe kynurenine pathway in schizophrenia and bipolar disorder
Erhardt, S., Schwieler, L., Imbeault, S., & Engberg, G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.020 · Cited by 255
Lim, C. K., Bilgin, A., Lovejoy, D. B., Tan, V., Bustamante, S., Taylor, B. V., Bessede, A., Brew, B. J., & Guillemin, G. J. (2017) · Scientific Reports · doi:10.1038/srep41473 · Cited by 255
Self-citationPresynaptic kynurenate‐sensitive receptors inhibit glutamate release
Carpenedo, R., Pittaluga, A., Cozzi, A., Attucci, S., Galli, A., Raiteri, M., & Moroni, F. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01592.x · Cited by 254
Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Sathyasaikumar, K. V., Stachowski, E. K., Wonodi, I., Roberts, R. C., Rassoulpour, A., McMahon, R. P., & Schwarcz, R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq112 · Cited by 253
Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia
Weickert, C. S., Fung, S. J., Catts, V. S., Schofield, P. R., Allen, K. M., Moore, L. T., Newell, K. A., Pellen, D., Huang, X.-F., Catts, S. V., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.137 · Cited by 236
Self-citationFillman, S. G., Sinclair, D., Fung, S. J., Webster, M. J., & Shannon Weickert, C. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.8 · Cited by 226
Schwieler, L., Larsson, M. K., Skogh, E., Kegel, M. E., Orhan, F., Abdelmoaty, S., Finn, A., Bhat, M., Samuelsson, M., Lundberg, K., et al. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140126 · Cited by 226
Thomas, S. R., & Stocker, R. (1999) · Redox Report · doi:10.1179/135100099101534927 · Cited by 208
Alberati‐Giani, D., Ricciardi‐Castagnoli, P., Köhler, C., & Cesura, A. M. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66030996.x · Cited by 187
Reduction of Brain Kynurenic Acid Improves Cognitive Function
Kozak, R., Campbell, B. M., Strick, C. A., Horner, W., Hoffmann, W. E., Kiss, T., Chapin, D. S., McGinnis, D., Abbott, A. L., Roberts, B. M., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1107-14.2014 · Cited by 180
Biomarkers in Schizophrenia: A Brief Conceptual Consideration
Weickert, C. S., Weickert, T. W., Pillai, A., & Buckley, P. F. (2013) · Disease Markers · doi:10.1155/2013/510402 · Cited by 175
Self-citationNanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum
Rassoulpour, A., Wu, H., Ferrė, S., & Schwarcz, R. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03134.x · Cited by 174
Boerrigter, D., Weickert, T. W., Lenroot, R., O’Donnell, M., Galletly, C., Liu, D., Burgess, M., Cadiz, R., Jacomb, I., Catts, V. S., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0962-y · Cited by 171
Self-citationWonodi, I., Stine, O. C., Sathyasaikumar, K. V., Roberts, R. C., Mitchell, B. D., Hong, L. E., Kajii, Y., Thaker, G. K., & Schwarcz, R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.71 · Cited by 166
Mitochondrial aspartate aminotransferase: a third kynurenate‐producing enzyme in the mammalian brain
Guidetti, P., Amori, L., Sapko, M. T., Okuno, E., & Schwarcz, R. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04556.x · Cited by 166
Guidetti, P., Hoffman, G. E., Melendez‐Ferro, M., Albuquerque, E. X., & Schwarcz, R. (2007) · Glia · doi:10.1002/glia.20432 · Cited by 156
Increased expression of astrocyte markers in schizophrenia: Association with neuroinflammation
Catts, V. S., Wong, J., Fillman, S. G., Fung, S. J., & Shannon Weickert, C. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414531078 · Cited by 148
Molecular Mechanisms and Timing of Cortical Immune Activation in Schizophrenia
Volk, D. W., Chitrapu, A., Edelson, J. R., Roman, K. M., Moroco, A. E., & Lewis, D. A. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15010019 · Cited by 135
Myint, A.-M., Schwarz, M., Verkerk, R. M., Mueller, H. H., Zach, J., Scharpé, S., Steinbusch, H. W. M., Leonard, B. E., & Kim, Y. K. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.05.005 · Cited by 125
Lavebratt, C., Olsson, S., Backlund, L., Frisén, L., Sellgren, C. M., Priebe, L., Nikamo, P., Träskman‐Bendz, L., Cichon, S., Vawter, M. P., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.11 · Cited by 119
Yao, J. K., Dougherty, G. G., Reddy, R. D., Keshavan, M. S., Montrose, D. M., Matson, W. R., Rozen, S., Krishnan, R. R., McEvoy, J., & Kaddurah-Daouk, R. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.33 · Cited by 118
Weinberg, D. D., Lenroot, R., Jacomb, I., Allen, K. M., Bruggemann, J. M., Wells, R., Balzan, R. P., Liu, D., Galletly, C. A., Catts, S. V., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.2925 · Cited by 113
Self-citationSelection of Reference Gene Expression in a Schizophrenia Brain Cohort
Weickert, C. S., Sheedy, D., Rothmond, D. A., Dedova, I., Fung, S., Garrick, T., Wong, J., Harding, A. J., Sivagnanansundaram, S., Hunt, C., et al. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048670903393662 · Cited by 106
Self-citationChiarugi, A., Carpenedo, R., Molina, M. T., Mattoli, L., Pellicciari, R., & Moroni, F. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65031176.x · Cited by 105
Condray, R., Dougherty, G. G., Keshavan, M. S., Reddy, R. D., Haas, G. L., Montrose, D. M., Matson, W. R., McEvoy, J., Kaddurah-Daouk, R., & Yao, J. K. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001689 · Cited by 98
Kynurenine pathway in psychosis: evidence of increased tryptophan degradation
Barry, S., Clarke, G., Scully, P., & Dinan, T. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089583 · Cited by 96 · cited 1×
“To determine the relationship of KP metabolites to cognitive performance and brain volumes, we focused solely on the KYN/TRP ratio given: (a) proinflammatory cytokines directly influence the KYN/TRP ratio by driving the metabolism of TRP to KYN via activation of IDO/TDO [9], (b) previously reported findings of an incr…”
MethodC. Prendergast, G., Y. Chang, M., Mandik-Nayak, L., Metz, R., & J. Muller, A. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795656072 · Cited by 96
Notarangelo, F. M., Wilson, E. H., Horning, K. J., Thomas, M. A. R., Harris, T. H., Fang, Q., Hunter, C. A., & Schwarcz, R. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2013.11.011 · Cited by 91
Chiappelli, J., Pocivavsek, A., Nugent, K. L., Notarangelo, F. M., Kochunov, P., Rowland, L. M., Schwarcz, R., & Hong, L. E. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.243 · Cited by 90
Anti-inflammatory treatment in schizophrenia
Müller, N., Myint, A.-M., Krause, D., Weidinger, E., & Schwarz, M. J. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.008 · Cited by 89
Serum testosterone levels are related to cognitive function in men with schizophrenia
Moore, L., Kyaw, M., Vercammen, A., Lenroot, R., Kulkarni, J., Curtis, J., O׳Donnell, M., Carr, V. J., Weickert, C. S., & Weickert, T. W. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.02.007 · Cited by 88
Self-citationTryptophan Metabolism and White Matter Integrity in Schizophrenia
Chiappelli, J., Postolache, T. T., Kochunov, P., Rowland, L. M., Wijtenburg, S. A., Shukla, D. K., Tagamets, M. A., Du, X. M., Savransky, A., Lowry, C. A., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.66 · Cited by 88
Heme: A Regulator of Rat Hepatic Tryptophan 2,3-Dioxygenase?
Ren, S., & Correia, M. A. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1755 · Cited by 80
Investigating the neuroimmunogenic architecture of schizophrenia
Birnbaum, R., Jaffe, A. E., Chen, Q., Shin, J. H., BrainSeq Consortium, Schubert, C. R., O'Donnell, P., Quan, J., Wendland, J. R., Xi, H. S., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.89 · Cited by 67 · cited 1×
“There are also studies that did not confirm an activation of the brain immune system in schizophrenia [56].”
ResultInfluence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia
Chiappelli, J., Notarangelo, F. M., Pocivavsek, A., Thomas, M. A. R., Rowland, L. M., Schwarcz, R. M., & Hong, L. E. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0038-4 · Cited by 50
Zavitsanou, K., Lim, C. K., Purves-Tyson, T., Karl, T., Kassiou, M., Banister, S. D., Guillemin, G. J., & Weickert, C. S. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.05.011 · Cited by 46
Self-citationChiappelli, J., Rowland, L. M., Notarangelo, F. M., Wijtenburg, S. A., Thomas, M. A. R., Pocivavsek, A., Jones, A., Wisner, K., Kochunov, P., Schwarcz, R. M., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0072-2 · Cited by 33
Okusaga, O. O., Fuchs, D., Reeves, G. M., Giegling, I., Hartmann, A. M., Konte, B., Friedl, M., Groer, M. E., Cook, T. B., Stearns‐Yoder, K. A., et al. (2016) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000352 · Cited by 31
Cited by
Tryptophan in health and disease
(2020) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2019.08.005 · Cited by 294
Tryptophan Metabolism as a Pharmacological Target
Modoux, M., Rolhion, N., Mani, S., & Sokol, H. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.006 · Cited by 284
Epidemiology, Pathophysiology, Diagnosis, and Management of Cerebral Toxoplasmosis
Elsheikha, H. M., Marra, C. M., & Zhu, X.-Q. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-19 · Cited by 262
Amino acid metabolism in tumor biology and therapy
Chen, J., Cui, L., Lu, S., & Xu, S. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06435-w · Cited by 255
The P2X7 Receptor: Central Hub of Brain Diseases
Andrejew, R., Oliveira-Giacomelli, Á., Ribeiro, D. E., Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00124 · Cited by 162
Metadata
- Authors
- Kindler, J., Lim, C. K., Weickert, C. S., Boerrigter, D., Galletly, C., Liu, D., Jacobs, K. R., Balzan, R., Bruggemann, J., O’Donnell, M., Lenroot, R., Guillemin, G. J., & Weickert, T. W.
- Venue
- Molecular Psychiatry
- Published
- 2019-04-03
- Volume
- 25
- Issue
- 11
- Pages
- 2860-2872
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2929017669
- Cited by
- 284
- References
- 56
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.